Immunexpress Announces Closing of Private Funding Round

Immunexpress.com

Immunexpress Announces Closing of Private Funding Round Funding will support the development of SeptiCyte™ RAPID through FDA 510(k) Clearance CE Marking of SeptiCyte™ RAPID anticipated in 1Q2020, FDA Clearance anticipated mid-2020 SEATTLE, Oct. 3, 2019 /PRNewswire/ — Immunexpress, Inc., a medical diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the closing of a major…

Read More